Keywords: Isis Pharma, Biogen Idec, Spinal muscular atrophy, SMA

Isis Pharma could earn $299 million from Biogen Idec deal

Article | 05 January 2012

US biotech firm Biogen Idec (Nasdaq: BIIB) has entered into an exclusive, worldwide option and collaboration agreement with Isis Pharmaceuticals ( ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Biogen Idec

Isis Pharmaceuticals

Go to company listing